RxDoctor Payments Data

Ryan Turpen, MD

Urology · Danville, KYNPI 1609957042

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,947 of the $12,546 with a category attached, or 63.3%. It is spread thinly across 46 manufacturers, the largest accounting for just 14.9%. Among urology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,546in general payments, 2019–2025

Across 426 payments — averaging $29.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$2K
  • Boston Scientific$2K
  • Neotract Inc.$2K
  • Astellas Pharma US Inc$1K
  • Johnson & Johnson$692
  • Antares Pharma, Inc.$516
  • plus $5K from 40 others

What the payments were for

  • Travel & lodging$3,96932%
  • Food & beverage$7,94763%
  • Education$6295%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,546 in reported general payments places this provider in the 90th percentile of 139 urology providers in Kentucky.

See all urology providers in Kentucky

Medicare billing

Part B allowed, 2024
$121,626
Medicare patients
435
Services billed
979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abiraterone Acetate29$104,061
MyrbetriqMirabegron135$88,904
GemtesaVibegron26$24,651
XyostedTestosterone Enanthate30$18,420
Potassium Citrate ErPotassium Citrate49$5,196
Testosterone34$4,593
Tamsulosin Hcl376$4,501
Testosterone Cypionate105$2,880
Dutasteride74$2,845
Finasteride191$2,405
Methenamine Hippurate26$1,959
Solifenacin Succinate70$1,409
Alfuzosin Hcl ErAlfuzosin Hcl55$1,018
Silodosin19$835
Estradiol14$805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,371$88,904135 claims
Sumitomo Pharma America, Inc.Gemtesa$297$24,65126 claims
Antares Pharma, Inc.Xyosted$516$18,42030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 139 urology providers in Kentucky.

Other urology in Danville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →